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Abstract
Male circumcision is associated with a lower risk of penile human papillomavirus (HPV) infection in human immunodeficiency virus
(HIV) uninfected men. Few studies have evaluated the role of male circumcision in penile HPV infection in HIV-infected men. The aim
of this cross-sectional study was to examine the association between male circumcision and the prevalence of penile HPV infection
among HIV-infected men—both men who have sex with men (MSM) and heterosexual men. Samples from 706 consecutive men
included in the CARH-MEN cohort (overall 24% circumcised: 26% of MSM, 18% of heterosexual men) were examined by Multiplex-
PCR. In the overall group (all HIV-infected men included), the prevalence of any penile HPV infection was 22% in circumcised men and
27% in uncircumcised men (OR = 1.0, 95% CI 0.6–1.6, adjusted analysis). In the circumcised group the overall prevalence of HPV infec-
tion was 22% in MSM and 24% in the heterosexual men, whereas in the uncircumcised group the prevalence was 26% and 28%, respec-
tively. The prevalence of high-risk HPV types tended to be lower in the circumcised MSM (14% vs 21%, OR = 0.6, 95% CI 0.3–1.1,
p 0.088), but it was similar in the heterosexual men (18% in circumcised vs 20% in uncircumcised). These results suggest that male cir-
cumcision may be associated with a lower prevalence of oncogenic high-risk penile HPV infection in HIV-infected MSM.
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Introduction
There is evidence that circumcision reduces the risk of
human immunodeficiency virus (HIV) acquisition in hetero-
sexual men by about 60% and it is recommended as one of
the HIV prevention strategies [1,2]. Though the prevalence
of penile human papillomavirus (HPV) infection varies around
the world [3], male circumcision is associated with a reduced
risk of penile HPV infection [4,5].
Infection with high-risk (HR) oncogenic HPV types is the
aetiological cause of several specific squamous cancers, such
as cervical, anal and oropharyngeal cancers. In contrast,
infection with low-risk (LR) HPV types (6 and 11) is the aeti-
ological cause of genital warts [6,7].
Most studies focusing on the role of circumcision in penile
HPV infection have been performed on HIV-uninfected men.
Only one randomized clinical trial of male circumcision
among HIV-infected men has been conducted reporting a
protective effect of circumcision on the prevalence of HR-
HPV types 24 months after the procedure [8]. However, no
information is available about the role of circumcision in
HIV-infected men who have sex with men (MSM). The objec-
tive of this cross-sectional analysis was to provide evidence
about the association between male circumcision and the
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prevalence of penile HPV infection among HIV-infected men
(MSM and heterosexual) in Spain.
Patients and Methods
Study design
A cross-sectional analysis, based on the first (baseline) visit
to the CARH-MEN (Can Ruti HIV-positive Men) cohort, was
performed. This cohort was a prospective, single-centre
study including HIV-positive outpatient men who were annu-
ally assessed for HPV infection of anus, penis and mouth.
The protocol, amendments and other materials were
approved by the hospital’s independent ethics committee [9].
Consecutive patients, who attended their AIDS routine con-
trol, were informed about the study and written informed
consent was obtained for recruitment to the current study.
HIV-positive men ‡18 years old, without history of (or
current) HPV-related pathology in anus, penis or mouth
were included in the CARH-MEN cohort between January
2005 and May 2009. At the baseline visit, all participants
completed a detailed self-administered baseline question-
naire, and a clinical examination (visual inspection) of the
three body areas studied (anal canal, penis and mouth) and a
digital rectal examination were performed. Samples from the
three areas were collected for detecting HPV infection. All
patients were monitored annually. At each annual visit, ques-
tionnaire and clinical examination were performed. The
following data were collected: date of birth, date of HIV-
positive diagnosis, baseline CD4 cell counts (the closest value
determined during participants’ usual clinical follow-up visits
in HIV Unit before the cytological sample collection), CD4
nadir counts (the lowest CD4 value of each patient
abstracted from medical records), plasma HIV viral load (the
closest value determined before the sample collection),
highly active antiretroviral therapy previous to inclusion and
time on highly active antiretroviral therapy, history of sexu-
ally transmitted infections, alcohol use and smoking history,
sexual behaviour and number of sexual partners. CD4 cell
count and CD4 nadir were determined by flow cytometry;
HIV viral load was measured by Nuclisens (bioMe´rieux, Inc.,
Durham, NC, USA).
Penile sample collection
Trained clinicians collected the first 2 cm of the urethral epi-
thelium with a dacron urethral swab. A second saline pre-
wetted dacron swab was used to obtain cells from the four
quadrants of the penile shaft, glans and coronal sulcus. The
glans was first scratched with sand paper to increase the cel-
lular yield. Both penile samples were pooled in the same
tube and suspended in 1 mL of 0.1 M phosphate-buffered sal-
ine and the solution was stored at )20C until analysis.
HPV testing and genotyping
DNA extraction was performed by the Qiamp Viral DNA
kit (QIAGEN, Hilden, Germany). HPV detection and typing
were performed using the commercial Multiplex Fluorescent-
PCR Kit (F-HPV typing, Molgentix SL, Barcelona, Spain) in
accordance with the manufacturer’s instructions. The assay
permits the detection of 13 HR-HPV types: 16, 18, 31, 33,
35, 39, 45, 51, 52, 56, 58, 59, 68; and two LR-HPV types: 6,
11. A human short tandem repeat sequence included in the
same multiplex was amplified as an internal control to check
for DNA integrity and the absence of PCR inhibitors. Prod-
ucts were analysed by capillary electrophoresis on an ABI
3130 XL genetic analyser and GENEMAPPER 4.0 software
(Applied Biosystems, Foster City, CA, USA). Each PCR run
included HPV-positive and HPV-negative controls. Particular
care was taken to prevent carry-over contamination by sepa-
rating pre-PCR and post-PCR areas in all PCR experiments.
Definitions
Sexual status, i.e. MSM or heterosexual, was obtained
through the questionnaire, and then verified by checking the
medical record. Circumcision status was obtained through
the questionnaire, and during the visual clinical inspection at
baseline visit. Existence of a current HPV infection was con-
sidered when one or more HPV types were detected in a
sample, single or multiple HPV infections if one or more
HPV types were detected respectively. LR-HPV infection was
defined as when only HPV-6 and/or HPV-11 was detected,
and HR-HPV infection as when any of HPV-16, 18, 31, 33,
35, 39, 45, 51, 52, 56, 58, 59 or 68 was detected. No HPV
infection was defined as non-detectable HPV types.
Statistical analysis
Three populations were analysed: the entire group (all HIV-
infected men included in the study), the MSM group and the
heterosexual group. Baseline characteristics were summa-
rized with standard descriptive statistics and a descriptive
analysis was carried out. Differences between circumcised
and uncircumcised men were evaluated by the chi-square
test for qualitative variables. Differences in the prevalence of
type-specific infections were also assessed by the circumci-
sion status. Odds ratios (OR) for prevalence were estimated
as well as the corresponding 95% CI. The association
between potential explanatory variables and HPV infection
was tested. A bivariate regression model was performed to
obtain an indication of the relevance of the explanatory vari-
ables for the risk of HPV infection. A multivariate regression
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model using a stepwise selection of variables was adjusted to
the following covariates: the presence of circumcision; his-
tory of anal warts; history of sexually transmitted infections;
receptive anal intercourse (yes/no); number of lifetime sexual
partners (>25); HIV infection time (years); plasma HIV-1
RNA (undetectable <50 copies/mL); nadir CD4 counts
(<200 cells/mm3); and CD4 counts at baseline (<200 cells/
mm3). A p value £0.05 was considered statistically significant.
Data analysis was carried out using SPSS version 15.0 statisti-
cal software (Chicago, IL, USA).
Results
Patients’ characteristics
The CARH-MEN cohort included 733 HIV-positive men (538
MSM and 195 heterosexuals), a total of 706 (96%) patients
with available and concordant circumcision information from
clinician assessment and patients’ self-reported questionnaire
were included in the present analyses. The overall prevalence
of circumcision was 24% (167/706): 26% (133/516) in MSM
and 18% (34/190) in heterosexual men (OR = 1.6; 95% CI
1.0–2.4, p 0.029). There were no significant differences in
the baseline characteristics between circumcised and uncir-
cumcised patients, except for a slightly higher proportion of
MSM in the circumcised group (Table 1).
Sixty-nine (10%) penile samples were not suitable for HPV
detection because of the lack of amplification of the internal
PCR control. Therefore, penile HPV prevalence was esti-
mated on 637 HIV-infected men: 143 circumcised (110 MSM
and 33 heterosexual) and 494 uncircumcised (340 MSM and
154 heterosexual).
Overall HIV-infected men group
The overall prevalence of any penile HPV infection was 26%
(163/637, 95% CI 22–29), 22% (32/143, 95% CI 16–30) in
the circumcised group and 27% (131/494, 95% CI 23–31) in
the uncircumcised group. This difference was not statistically
significant (Table 2).
The risk factors associated with any penile HPV infection
in the adjusted analysis were a history of anal warts
(OR = 2.4, 95% CI 1.5–3.8), receptive anal intercourse
(OR = 3.3, 95% CI 2.1–5.4), number of sexual lifetime part-
ners (>25) (OR = 2.1, 95% CI 1.2–3.7) and CD4 counts
lower than 200 cells/mm3 (OR = 1.4, 95% CI 1.1–2.0). In
contrast, undetectable HIV load in plasma (OR = 0.6, 95% CI
0.3–0.9) was a protective factor for any HPV infection.
The analysis of any penile HPV infection prevalence by cir-
cumcision status and stratified by plasma HIV load (detect-
able: >50 copies/mL and undetectable: <50 copies/mL), and
by CD4 nadir counts (200 cells/mm3) did not show differ-
ences.
HPV-16 (6% (8/143) circumcised, 5% (26/494) uncircum-
cised) was the most common type detected among the high-
risk types, and HPV-6 (7% (10/143) circumcised, 9% (44/494)
uncircumcised) was commonest among the low-risk types
(Fig. 1). The only statistical difference observed in the analy-
ses for specific types was for HPV-51, which was less
prevalent in circumcised men (1% vs 4%, OR = 0.2, 95% CI
0.1–0.9, p 0.048).
TABLE 1. Baseline characteristics of human immunodefi-
ciency virus (HIV) -infected men based on circumcision sta-
tus
Baseline characteristics
Circumcised
n = 167
Uncircumcised
n = 539 p-value
Age
Median years (Range) 40 (21–70) 42 (20–77) 0.256
20–29 years, n (%) 11 (6.6) 42 (7.8)
30–39 years, n (%) 65 (38.9) 171 (31.7)
40–49 years, n (%) 67 (40.1) 233 (43.2)
50–59 years, n (%) 17 (10.2) 72 (13.4)
60–69 years, n (%) 6 (3.6) 17 (3.2)
>69 years, n (%) 1 (0.6) 4 (0.7)
Time of known HIV (years)
Median (Rangea) 9 (0–24) 9 (0–26) 0.582
AIDS diagnosis (Yes), n (%) 28 (16.8) 84 (15.6) 0.715
HIV plasma load
< 50 HIV RNA copies/mL, n (%)
111 (66.9) 356 (66.8) 0.986
CD4 cell count at baseline, n (%)
<200 cells/mm3 11 (6.6) 33 (6.2) 0.979
200–500 cells/mm3 70 (42.2) 225 (42.2)
>500 cells/mm3 85 (51.2) 275 (51.6)
CD4 nadir Mean (95% CI) 255 (227–282) 260 (245–276) 0.876
<200 cells/mm3, n (%) 67 (40.1) 213 (39.5) 0.889
HAART previous to inclusion (Yes)
Number (%) 136 (81.4) 453 (84) 0.428
Duration of HAART (years)
Median (25–75 centile) 6 (5–6.7) 6 (5.6–6) 0.887
History of STI (Yes)
Number (%) 63 (37.7) 235 (43.6) 0.176
Alcohol history, n (%)
Never 39 (24.7) 135 (25.8) 0.357
Current 93 (58.9) 278 (53.2)
Past 26 (16.5) 110 (21)
Smoking history, n (%)
Never 32 (20.3) 126 (24.1) 0.129
Current 98 (62) 277 (53)
Past 28 (17.7) 120 (22.9)
Injected drug user, n (%)
Never 135 (84.9) 416 (79.8) 0.329
Current 2 (1.3) 6 (1.2)
Past 22 (13.8) 99 (19)
Number of sexual partners, n (%)
1 partner 1 (0.6) 7 (1.3) 0.906
2–9 partners 21 (12.6) 78 (14.5)
10–25 partners 17 (10.2) 56 (10.4)
>25 partners 104 (62.3) 322 (59.7)
Men having sex with men, n (%) 133 (79.6) 383 (71.1) 0.029
History of RAI (Yes), n (%) 98 (67.1) 293 (60.4) 0.143
HAART, highly active antiretroviral therapy; STI, sexually transmitted infection;
RAI, receptive anal intercourse.
aRange (maximum–minimum values).
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High-risk HPV types were detected in all multiple penile
HPV infections. History of anal warts and nadir CD4 counts
below 200 cells/mm3 were associated with higher rate of
infection with HR-HPV (Table 3).
MSM HIV-infected group
The prevalence of any penile HPV infection in MSM was 25%
(112/450, 95% CI 21–29) (Table 2). The only risk factor
associated with any penile HPV infection in the adjusted anal-
ysis was a history of anal warts (OR = 2.7, 95% CI 1.4–5.2).
CD4 counts >200 cells/mm3 were shown to be a protective
factor (OR = 0.5, 95% CI 0.3–0.8).
The prevalence for HR-HPV types tended to be lower in
circumcised MSM compared with uncircumcised MSM (14%
vs 21%, OR = 0.6, 95% CI 0.3–1.1) (Table 2). Circumcision
was associated with a statistically non-significant lower fre-
quency of penile HR-HPV infection (OR = 0.6, 95% CI 0.3–
1.1, p 0.088, adjusted analysis) (Table 3).
Heterosexual HIV-infected group
The prevalence for any penile HPV infection in heterosexual
men was 27% (51/187, 95% CI 21–34). No differences were
observed between the circumcised and uncircumcised groups
(Table 2). No significant risk factor in the adjusted analysis
TABLE 2. Prevalence of human papillomavirus (HPV) infection in human immunodeficiency virus (HIV) -infected men accord-
ing to circumcision status and sexual behaviour
Penile HPV
infection
Overall HIV-infected men (n = 637) HIV-infected MSM (n = 450) HIV-infected heterosexuals (n = 187)
Circumcised
n = 143
Uncircumcised
n = 494 Crude values
Circumcised
n = 110
Uncircum-
cised n = 340 Crude values
Circumcised
n = 33
Uncircum-
cised n = 154 Crude values
n % (95% CI) n % (95% CI) OR (95% CI) n % (95% CI) n % (95% CI) OR (95% CI) n % (95% CI) n % (95% CI) OR (95% CI)
Any type 32 22
(16–30)
131 27
(23–31)
0.8
(0.5–1.2)
24 22
(14–30)
88 26
(21–30)
0.8
(0.5–1.3)
8 24
(11–42)
43 28
(21–36)
0.8
(0.4–2.0)
High-risk typesa 21 15
(9–22)
101 20
(17–24)
0.6
(0.4–1.1)
15 14
(8–21)
70 21
(16–25)
0.6
(0.3–1.1)
6 18
(7–35)
31 20
(14–27)
0.9
(0.3–2.3)
Low-risk typesb 11 8
(4–14)
30 6
(8–14)
0.7
(0.4–1.4)
9 8
(4–17)
18 5
(4–10)
1.5
(0.6–3.4)
2 6
(1–24)
12 8
(5–16)
0.7
(0.2–3.5)
Single (1 type) 25 17
(12–25)
86 17
(14–21)
1.0
(0.6–1.6)
19 17
(11–26)
55 16
(12–20)
1.1
(0.6–1.9)
6 18
(7–35)
31 20
(14–27)
0.8
(0.3–2.3)
Multiple (‡2 types) 7 5
(2–10)
45 9
(7–12)
0.5
(0.2–1.1)
5 4
(1–10)
33 10
(7–13)
0.4
(0.2–1.2)
2 6
(1–20)
12 8
(4–13)
0.7
(0.2–3.6)
MSM, men who have sex with men.
aIncluded infections with any of the high-risk types:HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68.
bIncluded infections only containing low-risk types: HPV-11 and/or HPV-6.
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FIG. 1 Prevalence of infection with human papillomavirus (HPV)
type: low-risk (HPV-6, -11) and high-risk oncogenic (HPV-16, -18, -
31, -33, -35, -39, -45, -51, -52, -56, -58, -59, -68) by circumcision sta-
tus.
TABLE 3. Predictive factors associated with the presence of
high risk human papillomavirus (HPV) types in penis of
human immunodeficiency virus (HIV) -infected men in the
three populations analysed: overall group (all HIV-infected
patients included in the study), men who have sex with men
group and heterosexual men; multivariate analyses
High risk HPV infection
Adjusteda
OR (95% CI) p-valueb
Overall (n = 637)
Circumcision (yes/no) 0.7 (0.4–1.2) 0.158
History of anal wartsc 1.7 (1.1–2.6) 0.023
Nadir CD4 counts (<200 cells/mm3) 1.6 (1.1–2.5) 0.026
Men who have sex with men (n = 450)
Circumcision (yes/no) 0.6 (0.3–1.1) 0.088
Nadir CD4 counts (<200 cells/mm3) 1.7 (0.9–3.0) 0.079
CD4 counts at baseline (<200 cell/mm3) 2.6 (0.9–7.7) 0.086
Heterosexual men (n = 187)
Circumcision (yes/no) 0.9 (0.3–2.6) 0.784
Undetectable plasma HIV-1 RNA
(<50 copies/mL)
0.4 (0.2–0.8) 0.014
aMultivariate analysis was adjusted for circumcision and the following covariates:
history of anal warts, history of sexual transmitted infections, receptive anal
intercourse (yes/no), number of lifetime sexual partners (>25), HIV infection
time (years), plasma HIV-1 RNA (non-detectable <50 copies/mL), nadir CD4
counts (<200 cells/mm3), and CD4 counts at baseline (<200 cells/mm3).
bp <0.05, differences statistically significant.
cIncluded men with history or presence of anal condylomatous lesions at base-
line.
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was found, although having a history of anal warts showed
similar results to the MSM group (OR = 1.9, 95% CI 0.9–4.0,
p 0.065).
A similar prevalence of penile HR-HPV infection was
observed by circumcision status (Table 2). An undetectable
plasma level of HIV load was a protective factor for HR-HPV
(Table 3).
Discussion
To our knowledge, this is the first study providing data on
the prevalence of penile HPV infection by circumcision status
in HIV-infected MSM and heterosexual men without a history
of penile warts in a developed country (Spain). The preva-
lence of any penile HPV infection was 22% in the circumcised
men and 27% in uncircumcised men. This prevalence was
similar between MSM and heterosexual men, regardless of
circumcision status. However, the prevalence of HR-HPV
types tended to be lower in circumcised MSM.
A recent meta-analysis, based mainly on HIV-negative
men, indicated that circumcised men were less likely to have
prevalent genital HPV infection than uncircumcised men, but
with important between-study heterogeneity [10]. Only one
published randomized clinical trial studied the effect of male
circumcision on penile HPV infection among HIV-infected
men [8]. This randomized clinical trial, carried out in Africa,
randomized HIV-infected patients to immediate versus
delayed (at 24 months) circumcision, showing an effect of
circumcision on prevalence of HR-HPV types at 24 months
(OR = 0.49; 95% CI 0.26–0.93). This study also showed a
high incidence of HPV (50% over 24 months), borderline evi-
dence of a protective effect of circumcision on HPV inci-
dence (RR = 0.68; 95% CI 0.44–1.04) and no evidence of a
protective effect of circumcision on HPV clearance
(RR = 1.09; 95% CI 0.94–1.27) [8]. It is noteworthy that the
prevalence of penile HPV infection observed in our study in
uncircumcised HIV-infected men was lower (27%) than the
prevalence of the abovementioned randomized clinical trial
at baseline. Furthermore, it should be taken into account
that 73% of the HIV-infected men included in our study were
MSM (22% prevalence of penile HPV infection). Moreover, in
a previous study of the present cohort a high prevalence of
anal condylomata was related to a high prevalence of HR-
HPV and high-grade squamous intraepithelial lesions in the
anal canal [11]. Hence, it is reasonable to think that the anus
may be a reservoir for these types and might contribute to
penile HPV infection or re-infections.
Some limitations need to be considered in the interpre-
tation of these results. The study design (cross-sectional)
cannot provide evidence on the effect of male circumcision
on penile HPV infection; it only shows associations. Cir-
cumcision prevalence varies, depending on the country,
from 6% (the Netherlands), 21% (UK) and 80% (USA and
South Korea) to 87% (Kenya) [12]. The prevalence of cir-
cumcision found among the HIV-infected men (24%) was
that expected for European countries. Different rates of
circumcision may be responsible for the diversity of results
between studies. The small sample size of circumcised het-
erosexual HIV-infected men does not allow for conclusions
to be drawn for this subpopulation in our study. Other
drawbacks may be the anatomical site of HPV sampling
(glans/corona, penile shaft, scrotum, urethra). In our study,
the penile sample was pooled from the urethral epithe-
lium, penile shaft, glans and coronal sulcus. In conse-
quence, it was not possible to provide information on
HPV infection for each distinct area. The HPV-DNA detec-
tion method used only targets 13 HR-HPV and two LR-
HPV types. The HR-HPV types are the most commonly
associated with malignant lesions in anogenital sites and
the LR-HPV types are the most involved in anogenital con-
dylomatous lesions. Therefore, the method used for HPV-
DNA detection provides information on clinically relevant
types.
In summary, male circumcision may be associated with a
lower prevalence of oncogenic high-risk penile HPV
types in HIV-infected MSM. Further longitudinal clinical
studies, preferably randomized clinical trials, are needed in
different areas of the world, to assess the potential
benefit of male circumcision on penile HPV infection in
HIV-infected men, thereby preventing potential penile
cancer.
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